[18F]FTT Positron Emission Tomography/Computed Tomography for the Imaging of Pancreatic Neuroendocrine Tumors
This phase I trial studies whether a special type of radioactive imaging drug ([18F]FTT), called a "radioactive tracer", can help doctors see sites of pancreatic neuroendocrine tumors more clearly when used with a procedure called positron emission (PET)/computed tomography (CT). PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, [18F]FTT. [18F]FTT attaches to a protein called PARP-1, which is expressed by some types of tumor cells. 18F-FTT is used to create pictures or images of areas that might have PARP-1 activity from the pancreatic neuroendocrine tumor and can be seen on PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient’s body. [18F]FTT PET/CT may be effective way to image pancreatic neuroendocrine tumors.